Trump announces trade deal with EU following months of negotiations
Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), a $2.8 billion market cap biotechnology company with a Fair overall financial health rating according to InvestingPro, recently sold 2,940 shares of the company’s common stock. The shares were sold at an average price of $53.135 each, amounting to a total transaction value of $156,216. With the stock currently trading at $46.20, down from the transaction price but up 27% over the past year, the timing appears notable. Following this transaction, Chess directly owns 18,173 shares of Twist Bioscience.
The sale was conducted to cover tax liabilities associated with the vesting of Restricted Stock Units, as part of a pre-arranged, irrevocable plan. This transaction does not reflect a discretionary trade by Chess. Additionally, Chess indirectly holds 42,528 shares through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries. For comprehensive insider trading analysis and 7 additional key insights about TWST, visit InvestingPro.
In other recent news, Twist Bioscience has been the focus of several analyst upgrades following its robust financial performance. Scotiabank (TSX:BNS) analyst Sung Ji Nam raised the company’s price target to $62 from $54, following Twist Bioscience’s first quarter financial results for fiscal year 2025 that surpassed consensus predictions. The company reported gross margins for the quarter that exceeded the prior year’s guidance and revised its full-year fiscal 2025 guidance upward.
At the same time, Barclays (LON:BARC) analyst Luke Sergott increased the price target on Twist Bioscience shares to $58, citing the company’s growing momentum in its Express portfolio and Next-Generation Sequencing (NGS) tools. Twist Bioscience’s strategic focus on its core portfolio and cost-effective management of investments have positioned it favorably in the eyes of Barclays analysts.
Baird also reaffirmed its positive stance on Twist Bioscience, maintaining an Outperform rating and a $48.00 price target. The firm’s analyst highlighted the consistent pricing premiums for the company’s Express Genes service, suggesting strong demand for the company’s offerings.
TD Cowen maintained its Buy rating and a price target of $58.00 for Twist Bioscience, based on the company’s solid financial guidance for fiscal year 2025. The firm’s confidence is attributed to management’s proven track record and competency in execution.
Lastly, following Twist Bioscience’s strong performance at the end of fiscal year 2024, Scotiabank raised its price target to $54 from the previous target of $50. The firm’s decision follows Twist Bioscience’s strong performance, surpassing consensus and guidance in all aspects. These are the recent developments surrounding Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.